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Organogenesis: Making Pancreas
from Liver
Dispatch
Valerie A. McLin1 and Aaron M. Zorn2
Making endocrine pancreas cells at will is one of the
major goals of cellular based therapies for diabetes.
The experimentally induced conversion of hepato-
cytes into pancreatic cells, using a modified version
of the transcription factor Pdx-1, may provide an
alternative to stem cell approaches.
The promise of tissue replacement therapy — that is,
of replacing a body’s damaged or diseased cells with
healthy or genetically corrected cells— has driven an
intensive search for methods to produce the desired
cells or tissue types in vitro. For example, the ability to
generate insulin-producing pancreatic β cells in vitro,
which could be transplanted into patients, would be
invaluable in treating hundreds of millions of diabetics
worldwide. Most of the research aimed at producing
therapeutically useful cells has focused on the
identification, isolation and in vitro differentiation of
stem cells.
As reported recently in Current Biology, Horb and
co-workers [1] have taken an alternative approach,
attempting to exploit the phenomenon of ‘transdiffer-
entiation’ — the conversion of one differentiated 
cell type into another. They have been able to induce
the conversion of liver cells into both endocrine 
and exocrine pancreatic cells by expressing in hepa-
tocytes a modified version of the pancreatic home-
obox gene Pdx-1. We shall review their results,
highlighting the significant advances and comment-
ing on some of the future hurdles that need to be
tackled before this type of approach might reach its
therapeutic potential.
Transdifferentiation is the term used to describe the
process whereby one differentiated cell type trans-
forms into another differentiated cell or tissue [2].
In vivo, this phenomenon is more commonly known 
as metaplasia and is frequently deemed a premalig-
nant lesion [3,4]. Transdifferentiation between the liver
and pancreas has been observed in human autopsy
and biopsy specimens. For example, transformation 
of many endodermal organs into hepatic tissue has
been observed in pathology specimens of digestive
tract tumors from adenocarcinoma of the stomach 
to pancreatic islet cell and ductular tumors [5]. Liver 
to pancreas transformations have also been observed
in liver cirrhosis, where the regenerating liver adopts 
an acinar histology resembling exocrine pancreatic
tissue [6]. Experimental models for transdifferentia
-tion between liver and the exocrine pancreas have
also been documented. For example, liver can be
converted into exocrine pancreas tissue in rats treated
with polychlorinated biphenyls [7] or in fish treated with
diethylnitrosamine [8]. But in all reported cases of 
pancreas transdifferentiated from liver, only exocrine
tissue and never endocrine pancreas tissue has 
been observed.
With the aim of converting liver cells into pancreas
tissue, including endocrine cells, Horb et al. [1]
developed a transgenic strategy using Xenopus and
expressed a superactive form of the pancreatic
homeobox gene Pdx-1 (also known as Xlhbox8) [9] in
the Xenopus embryonic liver [1]. Pdx-1 is a homeobox
transcription factor which is thought to be a key
determinant of pancreatic development. Targeted
deletion of Pdx-1 in mouse results in a failure of the
pancreas to form [10,11] and Pdx-1 mutations in
humans have been linked to pancreatic agenesis [12].
These results suggested that Pdx-1 might be a
‘master regulatory’ gene specifying the pancreatic
lineage [13], though earlier attempts to produce
ectopic pancreas tissue by overexpressing Pdx-1
were unsuccessful [14,15]. 
Horb et al. [1] reasoned that the earlier attempts to
induce a complete conversion of liver into pancreatic
tissue might have failed because Pdx-1 normally
needs other pancreas-specific cofactors to transacti-
vate its target genes and hence initiate pancreatic
development. They sought to overcome this by fusing
the potent VP16 transcriptional activation domain from
Herpes simplex virus [16] to Pdx-1, thus making a
super-active form of the protein, which they call
Xlhbox8-VP16, that might not require cofactors.
Using the liver-specific transthyretin (TTR) promoter,
Xlhbox8-VP16 was expressed in the liver buds of
transgenic embryos [1]. The transgene construct also
included a green fluorescent protein (GFP) reporter
under control of the pancreas-specific elastase pro-
moter, which directs expression in both the exocrine
and endocrine pancreas. This made it possible for
Horb et al. [1] to monitor the transition of liver to pan-
creas tissue in real time. They found that TTR-
Xlhbox8:VP16 transgenic animals indeed expressed
‘pancreatic-specific’ GFP in the liver bud, suggesting
the liver was transformed to pancreatic tissue. In
support of this, they observed ectopic expression of
endogenous endocrine pancreas markers, insulin and
glucagon, in what is normally liver tissue, with a
reciprocal loss of endogenous hepatic markers [1]. 
It is unclear, however, if the cells expressing ectopic
pancreas markers go on to form histologically rec-
ognizable pancreatic structures indicating functional
exocrine and endocrine tissue formation.
Importantly, Horb et al. [1] found that the Xlhbox8-
VP16 transgene was not expressed until a day or so
after the liver bud had started expressing hepatic
markers. They argue this indicates that they are
observing a transdifferentiation event, rather than
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redirecting the development of some naïve endoder-
mal precursor common to the liver and pancreatic
lineage. To further test this, the authors transfected
the human hepatoma-derived cell line HepG2, which
exhibits a number of characteristics of differentiated
hepatocytes, with the TTR-Xlhbox8:VP16 construct
[17]. In agreement with their observations on trans-
genic embryos, they found that Xlhbox8:VP16 induced
in the HepG2 cells ‘pancreatic’ GFP expression from
the elastase:GFP reporter, expression of endogenous
exocrine and endocrine pancreatic markers, and
downregulation of liver gene expression [1].
The take-home message from these ‘proof-of-
principle’ experiments is that it might be possible to
convert a patient’s own hepatocytes into endocrine
pancreatic cells (Figure 1) as a means to alleviate
diabetes. Obviously, DNA delivery to the tissue of inter-
est is one of the major hurdles to overcome before
such gene-therapy becomes a viable therapeutic alter-
native. Horb et al. [1] make the interesting point that, in
the transgenic experiments, the TTR:Xlhbox8-VP16
transgene is shut off as the hepatocytes adopt their
new pancreatic fate. Thus, while the transgene expres-
sion is transient, the ectopic pancreatic tissue persists.
Hypothetically, this has exciting therapeutic possibili-
ties, in that no permanent genetic modification would
be necessary if one had a means of transiently trans-
fecting such a construct into an adult liver. The trans-
fected DNA would eventually be lost, but the new
endocrine cells might persist.
Is this approach applicable to other cell types?
Transdifferentiation phenomena are not limited to
endodermal organs and have been observed in both
mesodermal and ectodermal tissues [18,19]. It
appears, though, that the closer the embryological
relationship between two cell types, the more likely
one is to observe a conversion from one to the other
[2,19]. Indeed, the liver and pancreatic lineages arise
from a common embryonic endoderm cell population
in the anterior foregut. The decision between a hepatic
or pancreatic fate is thought to be regulated by only
few key developmental steps, such as fibroblast
growth factor from the adjacent heart promoting the
hepatic over a pancreatic fate [20], and the subsequent
expression of Pdx-1 in the presumptive pancreatic
lineage (Figure 1). The ability ectopically to activate
one of the key developmental regulators underpins the
success of the experiments reported by Horb et al. [1].
In order for similar approaches to be used with other
cell types, a detailed knowledge of their key develop-
mental regulators would be required.
Another important parameter in transdifferentiation
is the developmental stage or differentiation state of
the cells. It appears that the more immature, fetal or
transformed the cell type, the more readily transdiffer-
entiation can occur — as mentioned above, it is often
associated with premalignant neoplasias [3]. It could
be argued that both the liver bud and the tumor-
derived HepG2 cells are not true differentiated hepato-
cytes, but only partially differentiated hepatoblast- type
cells which may be more plastic in their ability to trans-
differentiate. Thus, to be therapeutically useful it will be
important in the future to test if adult hepatocytes can
be induced to form functioning pancreatic tissue. A
test of this might be to express Pdx1-VP16 in the liver
of adult mice with an inducible transgenic strategy and
determine if the mature hepatocytes can be converted
to pancreas.
Clearly, there are still numerous steps to be rigor-
ously examined before this approach can be consid-
ered a viable therapeutic option. However, Horb et al.
[1] have demonstrated an important and interesting
alternative to stem cell approaches, indicating that
transdifferentiation may indeed be an important route
to effective tissue replacement therapy in the future.
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Figure 1.
(A) Normal embryonic development of the closely related liver
and pancreas lineages. Pluripotent endoderm tissue in the
developing foregut that receives a fibroblast growth factor
(FGF) signal from adjacent heart tissue is specified along a liver
lineage and forms hepatoblasts. Nearby cells of the same
pluripotent endoderm, which do not receive the cardiac FGF
signal, adopt a pancreatic fate and express the homeobox
gene Pdx-1. Hepatoblasts go on to differentiate into hepato-
cytes and bile duct cells, while the pancreatic precursor ulti-
mately gives rise to all the endocrine and exocrine cell types of
the pancreas. (B) Experimentally induced transdifferentiation of
liver into pancreas. Expression of recombinant Pdx1-VP16 in
differentiating hepatocytes converts those cells into pancreatic
precursors which go on to give rise to both endocrine and
exocrine tissue.
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